MERRIMACK PHARMACEUTICALS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating expenses:
Research and development expenses
General and administrative expenses
Gain on sale of assets
Gain on sales of assets
Total operating expenses

Loss from operations
Other income and expenses:
Interest income
Interest expense
Other income (expense), net
Total other income and expenses

Loss before income tax expense
Income tax expense
Net loss from continuing operations
Income from discontinued operations, net of tax
Net loss
Unrealized gain on marketable securities
Other comprehensive loss
Net loss and comprehensive loss
Net income from discontinued operations, net of tax
Net loss per common share - basic and diluted
Weighted-average common shares used to compute basic and diluted net loss per common share
Cash dividends paid per common share
Net loss per common share - basic
Net loss per common share - diluted
Weighted-average common shares used to compute basic net loss per common share
Weighted-average common shares used to compute diluted net loss per common share

Comments